Revvity and Lilly partner to accelerate AI drug discovery models

Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering

US House passes Bill reauthorizing FDA rare disease incentive program

Lilly expands biotech footprint with new Gateway Labs in Philadelphia

The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio

Lilly opens biotech in San Diego

82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines

Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines

AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China

Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25

Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2

Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds

Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids